Welcome to the geko website

geko™ device

2018 marks the launch of our new website. We hope you like the fresh new look and improved navigation. The site places our clinical partners centre stage, and shines a light on their compelling research and readiness to embrace innovation to establish new therapies that address significant unmet need.

Pre-operative oedema reduction

The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust

Accelerating readiness for theatre
in ankle fracture patients

Read Less

Findings from our recent study have led us to adopt the geko™ device for all ankle and hind foot fractures in our unit. We are extremely pleased with the results we are getting.

We saw the potential to help ankle fracture patients become ready for theatre sooner and thought the geko™ device might provide the answer.

Working in partnership with Firstkind, we conducted a prospective and retrospective study to investigate use of the geko™ to reduce pre-operative oedema in ankle fracture patients requiring Open Reduction Surgical Fixation (ORIF).

We fitted the geko™ device above the backslab plaster cast and measured patient tolerance and readiness to theatre, matched to a historical cohort.

The study data was statistically significant in accelerating readiness for theatre: p=0.0011.

Results show:   

  • 2 days improvement in readiness to theatre per patient (average)
  • With geko™ use, 60% of patients ready for theatre in 2 days, compared to 27% in control arm, a 122% improvement.
  • Current treatment = 3.66 days readiness to theatre (average)
  • The geko™ + plaster cast = 1.66 days readiness to theatre (average)
  • The geko™ was well tolerated and easy to use.
  • Worn for 24 hours a day on the affected leg.
Enlarge

The geko™ device is cost saving

Independent health economic analysis shows routine use the geko™ device + backslab plaster cast, to accelerate readiness to theatre, saves an average of £5692 per patient, compared to current standards of care.

Benefits

2

2 days improvement in readiness to theatre (average).

60%

With geko™ use, 60% of patients ready for theatre in 2 days, a 122% improvement.

£569

Cost saving of £569 per patient (average).

References

  1. James Cook, retrospective data on file, April 2017, Firstkind.
  2. Health economic analysis performed subsequent to the completion of the study by Mtech Access Ltd, Bicester UK, 2017.
  3. Warwick D, et al. Neuromuscular electrostimulation via the common peroneal nerve promotes lower limb blood flow in a below-kneecast: A potential for thromboprophylaxis. Bone Joint Res 2013; 2:179–85
  4. Wainwright TW, Immins T, Middleton RG, Poster Physiotherapy UK, October 2014, Birmingham.
  5. A.Nicolaides, M Griffin, Measurement of blood flow in the deep veins of the lower limb using the geko™ neuromuscular electro-stimulation device. Journal of International Angiology August 2016-04.
  6. NICE medical technologies guidance (MTG19). Published date: June 20 2014.

OnPulse Technology

The revolutionary neuromuscular electrostimulation technology developed by Firstkind

Find out more

geko™ product

Hospital Applications device

Find out more

Partner with us

What can the geko™ do for my patients?

News

Sky Medical Technology Launches New geko™ Website

News

The geko™ device makes breakthrough in
pre-operative oedema reduction

News

Sky Medical Technology & the South Tees Hospitals NHS Foundation trust win prestigious Bionow award